The Application of Multimodal Artificial Intelligence Systems in Prostate Cancer Diagnosis and Prognosis Analysis

Launched by SHANGHAI CHANGZHENG HOSPITAL · Sep 6, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how advanced technology, specifically artificial intelligence (AI), can help improve the diagnosis and treatment of prostate cancer. The goal is to combine different types of information, like medical images and genetic data, to make more accurate decisions about prostate health. By doing this, researchers hope to enhance treatment options and improve the chances of survival for men with prostate cancer.

To participate in this trial, you need to be a male between 18 and 80 years old and have either a normal prostate, benign prostatic hyperplasia (a non-cancerous enlargement of the prostate), or prostate cancer. Additionally, you should have had a specific type of MRI scan of the prostate or pelvic area after January 1, 2014. Participants will undergo further assessments to see how this new AI technology can impact their diagnosis and treatment plans. If you have had certain other cancers recently or specific prostate surgeries, you may not be eligible for this study. Overall, this trial aims to harness the power of AI to create personalized care for men dealing with prostate issues.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Male, 18-80 years of age;
• • 2. Patients with normal prostate, prostatic hyperplasia, or prostate cancer who have undergone a prostate or pelvic magnetic resonance (MR) examination;
• • 3. First visit on January 1, 2014 or later.
• Exclusion Criteria:
• • 1. Patients with a diagnosis of any other malignancy within the previous 5 years;
• • 2. Patients who have undergone transurethral resection or enucleation of the prostate prior to undergoing imaging;
• • 3. Patients who are not suitable for participation in this clinical trial in the judgment of the investigator;
• • Patients who meet any of the above criteria may not be enrolled as subjects.